Paige, a pioneer in AI-based cancer diagnostics, has announced a strategic partnership with the Breast International Group (BIG), a global non-profit focused on breast cancer research. This collaboration aims to enhance diagnosis, treatment personalization, and outcomes for people with breast cancer through cutting-edge AI and world-class clinical expertise.
By leveraging Paige’s advanced AI technology and BIG’s extensive experience in global academic clinical trials and access to rich patient datasets, the partnership seeks to uncover insights that can refine biomarker detection, predict treatment responses, and support more targeted, cost-effective care. AI-powered diagnostics offer the potential to reduce testing turnaround time, streamline clinical decisions, and minimize unnecessary testing—preserving tissue and focusing resources where they’re most needed. A key focus of the collaboration will be addressing unmet needs in breast cancer care, including rare subtypes.
Central to the partnership is the evaluation of Paige’s OmniScreen™, an AI application that analyzes routine H&E-stained pathology slides to simulate a panel of 1,600 cancer biomarkers across 505 genes. This effort will explore how OmniScreen™ can help identify mutation-associated phenotypes in breast cancer. The collaboration will also investigate how AI can be used to standardize residual cancer burden measurement, support better patient stratification, and avoid over-treatment.
The ultimate goal is to embed AI tools earlier in diagnostic and research workflows, accelerating personalized care delivery and improving decision-making in clinical settings.
“This partnership reflects our belief that AI is no longer just a future promise—it’s solving real-world challenges today,” said Razik Yousfi, CEO and CTO of Paige. “Combining BIG’s leadership in breast cancer research with our AI capabilities will drive meaningful progress in cancer care.”
David Cameron, Chair of BIG and Professor of Oncology at Edinburgh University, added, “By integrating Paige’s innovative AI into our trials, we can deepen our understanding of tumor biology, enhance study design, and move faster toward more effective, personalized therapies. Our shared mission is to improve the lives of people with breast cancer.”